

Roberto F Machado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4178004/publications.pdf>

Version: 2024-02-01

148
papers

10,700
citations

57719

44
h-index

32815

100
g-index

150
all docs

150
docs citations

150
times ranked

11389
citing authors

#	ARTICLE	IF	CITATIONS
1	Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2410.	1.8	8
2	Cortactin Loss Protects Against Hemin-Induced Acute Lung Injury in Sickle Cell Disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, , .	1.3	2
3	IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias. <i>Blood</i> , 2021, 137, 1208-1218.	0.6	22
4	Cigarette Smoke and Nicotine-Containing Electronic-Cigarette Vapor Downregulate Lung WWOX Expression, Which Is Associated with Increased Severity of Murine Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 89-99.	1.4	5
5	Regional Variation in Methamphetamine-associated Pulmonary Arterial Hypertension: Who's™d Better Call Saul?. <i>Annals of the American Thoracic Society</i> , 2021, 18, 584-585.	1.5	4
6	Sphingosine Kinase 1 Regulates the Pulmonary Vascular Immune Response. <i>Cell Biochemistry and Biophysics</i> , 2021, 79, 517-529.	0.9	4
7	Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study. <i>British Journal of Haematology</i> , 2021, 194, 767-778.	1.2	6
8	The different facets of sickle cell disease-related pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 319-328.	1.2	4
9	<i>S100B</i> has pleiotropic effects on vaso-occlusive manifestations in sickle cell disease. <i>American Journal of Hematology</i> , 2020, 95, E62-E65.	2.0	1
10	Associations Between Mean Arterial Pressure and Poor ICU Outcomes in Critically Ill Patients With Cirrhosis: Is 65 The Sweet Spot?. <i>Critical Care Medicine</i> , 2020, 48, e753-e760.	0.4	19
11	Potential Contribution of Pulmonary Thromboembolic Disease in Pulmonary Hypertension in Sickle Cell Disease. <i>Annals of the American Thoracic Society</i> , 2020, 17, 899-901.	1.5	2
12	Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1543-1558.	1.1	20
13	MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase. <i>Scientific Reports</i> , 2019, 9, 9949.	1.6	6
14	Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. <i>Scientific Reports</i> , 2019, 9, 14802.	1.6	12
15	Validation of a composite vascular high-risk profile for adult patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E312-E314.	2.0	3
16	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2019, 16, e17-e32.	1.5	33
17	Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF- β 2 (Transforming Growth Factor- β 2)-Dependent Pulmonary Arterial Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1191-1202.	1.1	37
18	Transcriptome-wide analysis associates ID2 expression with combined pre- and post-capillary pulmonary hypertension. <i>Scientific Reports</i> , 2019, 9, 19572.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Vascular complications of sickle cell disease. <i>Clinical Hemorheology and Microcirculation</i> , 2018, 68, 205-221.	0.9	17
20	Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models. <i>Translational Research</i> , 2018, 197, 1-11.	2.2	15
21	Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	10
22	Death of the Endothelium in Sepsis: Understanding the Crime Scene. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 3-4.	1.4	17
23	Update in Pulmonary Vascular Disease 2016 and 2017. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 13-23.	2.5	6
24	Aberrant Caveolin-1-Mediated Smad Signaling and Proliferation Identified by Analysis of Adenine 474 Deletion Mutation (c.474delA) in Patient Fibroblasts: A New Perspective in the Mechanism of Pulmonary Hypertension. <i>Molecular Biology of the Cell</i> , 2018, , mbc.E16-06-0380.	0.9	1
25	Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 314, L461-L472.	1.3	33
26	HMOX1 and acute kidney injury in sickle cell anemia. <i>Blood</i> , 2018, 132, 1621-1625.	0.6	20
27	How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders. <i>Blood</i> , 2018, 132, 1770-1780.	0.6	16
28	A locus on chromosome 5 shows African ancestryâ€limited association with alloimmunization in sickle cell disease. <i>Blood Advances</i> , 2018, 2, 3637-3647.	2.5	18
29	Risk factors for vitamin D deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2018, 181, 828-835.	1.2	16
30	A Review of Transcriptome Analysis in Pulmonary Vascular Diseases. <i>Methods in Molecular Biology</i> , 2018, 1783, 259-277.	0.4	5
31	Interaction Between Pannexin 1 and Caveolin-1 in Smooth Muscle Can Regulate Blood Pressure. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2065-2078.	1.1	32
32	Hemolysis and hemolysisâ€related complications in females vs. males with sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E376-E380.	2.0	14
33	Reply to <sc>R</sc>uan <sc>X</sc> et al: â€A comment on pattern of opioid use in sickle cell diseaseâ€. <i>American Journal of Hematology</i> , 2017, 92, E43.	2.0	1
34	Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 1532-1546.	1.6	57
35	Hemin Causes Lung Microvascular Endothelial Barrier Dysfunction by Necroptotic Cell Death. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 307-314.	1.4	46
36	Association of circulating transcriptomic profiles with mortality in sickle cell disease. <i>Blood</i> , 2017, 129, 3009-3016.	0.6	22

#	ARTICLE	IF	CITATIONS
37	Inflammation-induced caveolin-1 and BMPRII depletion promotes endothelial dysfunction and TGF- β -driven pulmonary vascular remodeling. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L760-L771.	1.3	45
38	Loss of lung WWOX expression causes neutrophilic inflammation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 312, L903-L911.	1.3	17
39	APOL1, α -thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. <i>Haematologica</i> , 2017, 102, e1-e6.	1.7	47
40	Associations of α -thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts. <i>Blood Advances</i> , 2017, 1, 693-698.	2.5	12
41	Aberrant caveolin-1-mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension. <i>Molecular Biology of the Cell</i> , 2017, 28, 1177-1185.	0.9	30
42	Depletion of Caveolin-1 in Lung Vasculature and Increase in Caveolin-1 Positive Circulating Extracellular Vesicles as Early Biomarkers of Endothelial Injury. <i>FASEB Journal</i> , 2017, 31, .	0.2	0
43	<i>HMOX1</i> and Acute Kidney Injury in Sickle Cell Anemia. <i>Blood</i> , 2017, 130, 686-686.	0.6	0
44	Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. <i>PLoS ONE</i> , 2016, 11, e0163013.	1.1	11
45	Increased consumption and vasodilatory effect of nitrite during exercise. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 310, L354-L364.	1.3	8
46	Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. <i>Blood</i> , 2016, 127, 820-828.	0.6	109
47	Patterns of opioid use in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 1102-1106.	2.0	24
48	A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease. <i>Human Molecular Genetics</i> , 2016, 25, ddw299.	1.4	4
49	Pulmonary Vascular and Ventricular Dysfunction in the Susceptible Patient (2015 Grover Conference) Tj ETQq1 1 0,784314 rgBT /Ove 0,8	0,8	7
50	Expression Profiling Elucidates a Molecular Gene Signature for Pulmonary Hypertension in Sarcoidosis. <i>Pulmonary Circulation</i> , 2016, 6, 465-471.	0.8	10
51	PDGF induces SphK1 expression via Egr-1 to promote pulmonary artery smooth muscle cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , 2016, 310, C983-C992.	2.1	38
52	Pulmonary hypertension associated with thalassemia syndromes. <i>Annals of the New York Academy of Sciences</i> , 2016, 1368, 127-139.	1.8	46
53	Endothelial β -Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis. <i>Circulation</i> , 2016, 133, 177-186.	1.6	158
54	Pulmonary Complications of Hematologic Diseases. , 2016, , 1653-1670.e11.		1

#	ARTICLE	IF	CITATIONS
55	Associations of Prolonged QTc in Sickle Cell Disease. PLoS ONE, 2016, 11, e0164526.	1.1	20
56	Progressive Glomerular Damage in Sickle Cell Trait and Sickle Cell Anemia Mouse Models. Blood, 2016, 128, 3637-3637.	0.6	0
57	Racial Difference in Sarcoidosis Mortality in the United States. Chest, 2015, 147, 438-449.	0.4	174
58	Response. Chest, 2015, 147, e65-e66.	0.4	0
59	Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy. Haematologica, 2015, 100, 1275-1284.	1.7	60
60	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Human Genetics, 2015, 134, 895-904.	1.8	20
61	Conjunctival and pulmonary hemodynamic properties in sickle cell disease subjects with and without pulmonary hypertension. Clinical Case Reports (discontinued), 2015, 3, 1038-1041.	0.2	4
62	High sodium causes hypertension: evidence from clinical trials and animal experiments. Journal of Integrative Medicine, 2015, 13, 1-8.	1.4	17
63	Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L208-L220.	1.3	75
64	The Imitation Game in Pulmonary Arterial Hypertension. Sex, Bone Morphogenetic Protein Receptor, and the Estrogen Paradox. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 612-613.	2.5	4
65	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. Blood, 2015, 126, 3400-3400.	0.6	3
66	Upregulated Copper Transporters in Hypoxia-Induced Pulmonary Hypertension. PLoS ONE, 2014, 9, e90544.	1.1	44
67	Reply: Practice Guideline for Pulmonary Hypertension in Sickle Cell: Direct Evidence Needed before Universal Adoption. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 238-240.	2.5	1
68	Computed Tomography Correlates with Cardiopulmonary Hemodynamics in Pulmonary Hypertension in Adults with Sickle Cell Disease. Pulmonary Circulation, 2014, 4, 319-329.	0.8	7
69	Pulmonary Hypertension in Sickle Cell Disease. Annals of the American Thoracic Society, 2014, 11, 1488-1489.	1.5	22
70	Hypoxic Response Contributes to Altered Gene Expression and Precapillary Pulmonary Hypertension in Patients With Sickle Cell Disease. Circulation, 2014, 129, 1650-1658.	1.6	32
71	Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. British Journal of Haematology, 2014, 164, 729-739.	1.2	91
72	Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatric Respiratory Reviews, 2014, 15, 4-12.	1.2	97

#	ARTICLE	IF	CITATIONS
73	Nicotinamide Phosphoribosyltransferase Inhibitor Is a Novel Therapeutic Candidate in Murine Models of Inflammatory Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 51, 223-228.	1.4	37
74	The Sphingosine Kinase 1/Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1032-1043.	2.5	112
75	Mechanistic Insights and Characterization of Sickle Cell Disease-associated Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 430-437.	1.3	47
76	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 727-740.	2.5	197
77	Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 35-45.	0.6	23
78	ARTS: automated randomization of multiple traits for study design. <i>Bioinformatics</i> , 2014, 30, 1637-1639.	1.8	6
79	Nontuberculous Mycobacterial Disease Mortality in the United States, 1999-2010: A Population-Based Comparative Study. <i>PLoS ONE</i> , 2014, 9, e91879.	1.1	131
80	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. <i>PLoS ONE</i> , 2014, 9, e99489.	1.1	107
81	Updated Clinical Classification of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D34-D41.	1.2	2,865
82	A reliable and effective method of DNA isolation from old human blood paper cards. <i>SpringerPlus</i> , 2013, 2, 616.	1.2	9
83	Effect of Extended-Release Niacin on Serum Lipids and on Endothelial Function in Adults With Sickle Cell Anemia and Low High-Density Lipoprotein Cholesterol Levels. <i>American Journal of Cardiology</i> , 2013, 112, 1499-1504.	0.7	10
84	Pulmonary Hypertension Associated with Chronic Hemolytic Anemia and Other Blood Disorders. <i>Clinics in Chest Medicine</i> , 2013, 34, 739-752.	0.8	37
85	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. <i>Future Cardiology</i> , 2013, 9, 335-349.	0.5	34
86	Evaluation of a reliable and cost-effective method of DNA isolation for mouse genotyping. <i>Biotechnology Letters</i> , 2013, 35, 509-514.	1.1	1
87	Hemodynamic Predictors of Mortality in Adults with Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 840-847.	2.5	114
88	Optimization of Isolated Perfused/Ventilated Mouse Lung to Study Hypoxic Pulmonary Vasoconstriction. <i>Pulmonary Circulation</i> , 2013, 3, 396-405.	0.8	20
89	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. <i>Haematologica</i> , 2013, 98, 464-472.	1.7	170
90	Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin. <i>Haematologica</i> , 2013, 98, 455-463.	1.7	26

#	ARTICLE	IF	CITATIONS
91	Circulating Endothelial Progenitor Cells in Adults with Sickle Cell Disease. <i>Pulmonary Circulation</i> , 2013, 3, 448-449.	0.8	2
92	Hematologic and hemorheological determinants of resting and exercise-induced hemoglobin oxygen desaturation in children with sickle cell disease. <i>Haematologica</i> , 2013, 98, 1039-1044.	1.7	27
93	Transcriptional Events during the Recovery from MRSA Lung Infection: A Mouse Pneumonia Model. <i>PLoS ONE</i> , 2013, 8, e70176.	1.1	13
94	Genetic Association Of a MAPK8 Expression Quantitative Trait Locus With Pre-Capillary Pulmonary Hypertension In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 991-991.	0.6	0
95	A Novel Molecular Signature for Elevated Tricuspid Regurgitation Velocity in Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 359-368.	2.5	39
96	Sphingosine-1-Phosphate Receptor ³ Is a Novel Biomarker in Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 628-636.	1.4	73
97	Mortality in Adults With Sickle Cell Disease and Pulmonary Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1254.	3.8	179
98	Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia. <i>Haematologica</i> , 2012, 97, 1768-1770.	1.7	17
99	Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. <i>Microvascular Research</i> , 2012, 84, 262-269.	1.1	17
100	Peripheral Blood Gene Expression as a Novel Genomic Biomarker in Complicated Sarcoidosis. <i>PLoS ONE</i> , 2012, 7, e44818.	1.1	73
101	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. <i>Blood</i> , 2011, 118, 855-864.	0.6	210
102	NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. <i>British Journal of Haematology</i> , 2011, 154, 512-520.	1.2	51
103	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. <i>Circulation</i> , 2011, 124, 1452-1460.	1.6	124
104	Diagnostic and Therapeutic Algorithm for Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 122-124.	0.8	10
105	Perivascular T-Cell Infiltration Leads to Sustained Pulmonary Artery Remodeling after Endothelial Cell Damage. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 62-71.	1.4	30
106	Survival in Pulmonary Arterial Hypertension: A Brief Review of Registry Data. <i>Pulmonary Circulation</i> , 2011, 1, 430-431.	0.8	18
107	Clinical and Genetic Variability of Red Blood Cell Hemolysis in Sickle Cell Anemia. <i>Blood</i> , 2011, 118, 1077-1077.	0.6	6
108	Integration of Genomic and Genetic Approaches Highlight a Novel Validated Gene Signature for Pulmonary Hypertension Associated with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 511-511.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. <i>Blood</i> , 2011, 118, 1074-1074.	0.6	1
110	Genomic Assessment of Mortality in Sickle Cell Disease- A Novel Association with Cytokine Imbalance and T Cell Dysregulation. <i>Blood</i> , 2011, 118, 1081-1081.	0.6	0
111	Pulmonary Hypertension in Hemolytic Disorders. <i>Chest</i> , 2010, 137, 30S-38S.	0.4	71
112	Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. <i>Medical Physics</i> , 2010, 37, 1522-1532.	1.6	30
113	Diagnosis and Management of Pulmonary Hypertension in Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2010, 12, 8-18.	2.1	29
114	Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. <i>British Journal of Haematology</i> , 2010, 149, 426-435.	1.2	114
115	Pulmonary Complications of Hemoglobinopathies. <i>Chest</i> , 2010, 138, 973-983.	0.4	52
116	Categorization and impact of pulmonary hypertension in patients with advanced COPD. <i>Respiratory Medicine</i> , 2010, 104, 1877-1882.	1.3	147
117	Hemodynamic Parameters Predict Mortality In Sickle Cell Disease-Related Pulmonary Hypertension. <i>Blood</i> , 2010, 116, 2668-2668.	0.6	3
118	Pulmonary Complications of Hematologic Disease. , 2010, , 1999-2021.		0
119	Identifying Chronic Obstructive Pulmonary Disease and Asthma by Exhaled Breath Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1038-1039.	2.5	12
120	Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. <i>British Journal of Haematology</i> , 2009, 145, 506-513.	1.2	85
121	Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. <i>British Journal of Haematology</i> , 2009, 147, 737-743.	1.2	69
122	NT-Pro Brain Natriuretic Peptide Levels and the Risk of Stroke and Death in the Cooperative Study of Sickle Cell Disease.. <i>Blood</i> , 2009, 114, 1541-1541.	0.6	6
123	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.. <i>Blood</i> , 2009, 114, 571-571.	0.6	13
124	Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. <i>British Journal of Haematology</i> , 2008, 142, 971-978.	1.2	59
125	Pulmonary artery segmentation and quantification in sickle cell associated pulmonary hypertension. <i>Proceedings of SPIE</i> , 2008, , .	0.8	2
126	Pulmonary Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 324-31.	3.8	93

#	ARTICLE	IF	CITATIONS
127	CT and image processing non-invasive indicators of sickle cell secondary pulmonary hypertension. , 2008, 2008, 859-62.		0
128	Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1272-1279.	2.5	227
129	Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood, 2007, 110, 2166-2172.	0.6	316
130	Nitric oxide-based therapies in sickle cell disease: The evidence continues to mount*. Critical Care Medicine, 2007, 35, 654-655.	0.4	2
131	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. Journal of the American College of Cardiology, 2007, 49, 472-479.	1.2	265
132	Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. British Journal of Haematology, 2007, 136, 319-325.	1.2	109
133	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 2006, 107, 2279-2285.	0.6	561
134	N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2006, 296, 310.	3.8	169
135	Hemolytic Anemia Associated Pulmonary Hypertension. , 2006, , 170-187.		4
136	Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management, 2006, 2, 411-422.	1.0	127
137	Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood, 2005, 106, 734-739.	0.6	312
138	Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. British Journal of Haematology, 2005, 129, 449-464.	1.2	115
139	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology, 2005, 130, 445-453.	1.2	192
140	Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1286-1291.	2.5	514
141	Can the Electronic Nose Really Sniff out Lung Cancer?. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1060-1061.	2.5	7
142	Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients with Sickle Cell Disease.. Blood, 2005, 106, 206-206.	0.6	4
143	Platelet Activation Is Linked to the Severity of Pulmonary Hypertension in Sickle Cell Disease and Normalizes on Sildenafil Therapy.. Blood, 2005, 106, 3166-3166.	0.6	3
144	Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nature Medicine, 2004, 10, 1122-1127.	15.2	259

#	ARTICLE	IF	CITATIONS
145	Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radical Biology and Medicine, 2004, 37, 1010-1017.	1.3	75
146	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy.. Blood, 2004, 104, 235-235.	0.6	13
147	Low levels of nitric oxide and carbon monoxide in α 1-antitrypsin deficiency. Journal of Applied Physiology, 2002, 93, 2038-2043.	1.2	14
148	Hyperkalemia and Metabolic Acidosis Occur at Higher Estimated Glomerular Filtration Rates in Sickle Cell Disease. Kidney360, 0, , 10.34067/KID.0006802021.	0.9	3